Guidelines for Deprescribing in Multimorbidity: Evidence-Based Strategies for Optimizing Polypharmacy

Abstract

Deprescribing has emerged as a critical clinical process, particularly in patients with multimorbidity who are at high risk of polypharmacy and its associated adverse outcomes. This review synthesizes current evidence, expert recommendations, and recent guideline developments to provide a comprehensive, mechanism-based, and clinically relevant framework for deprescribing in adults with multiple chronic conditions. The article presents a structured approach for healthcare professionals to identify candidates for deprescribing, assess risks and benefits, and implement evidence-based interventions to enhance patient safety and optimize therapeutic outcomes.

Introduction

Multimorbidity, defined as the coexistence of two or more chronic diseases in an individual, is increasingly prevalent among aging populations worldwide. The management of multimorbidity often necessitates the use of multiple medications, leading to polypharmacy, which is commonly defined as the regular use of five or more medications. While polypharmacy may be clinically justified in certain cases, it is frequently associated with increased risks of adverse drug reactions (ADRs), drug-drug interactions, and medication nonadherence. Deprescribing—systematic withdrawal or dose reduction of inappropriate medications—has been recognized as a key strategy in improving outcomes for patients with multimorbidity. This review provides an in-depth analysis of the guidelines, evidence, and practical considerations for effective deprescribing in this complex patient population.

Epidemiology / Disease Burden

The prevalence of multimorbidity is rising, with recent studies indicating that up to 65% of adults aged 65 years and older have two or more chronic conditions. Polypharmacy affects more than 40% of older adults in developed nations, with a significant proportion exposed to potentially inappropriate medications (PIMs). The burden of medication-related harm is substantial: ADRs are responsible for approximately 10% of all hospital admissions in older adults, and polypharmacy is independently associated with increased morbidity, mortality, and healthcare costs. The epidemiological trends underscore the urgent need for systematic deprescribing interventions in clinical practice.

Pathophysiology

The pathophysiology underlying polypharmacy-related harm is multifactorial. Age-related pharmacokinetic and pharmacodynamic changes, such as reduced renal and hepatic clearance and altered receptor sensitivity, increase susceptibility to drug toxicity and interactions. In multimorbid patients, the cumulative impact of multiple disease states further complicates medication metabolism and efficacy. Chronic inflammation, frailty, and cognitive impairment can potentiate drug sensitivity, while polypharmacy itself disrupts homeostatic mechanisms, leading to a cascade of adverse clinical events. Understanding these mechanisms is critical for identifying individuals at highest risk and justifying deprescribing interventions from a biological standpoint.

Risk Factors

Risk factors for inappropriate polypharmacy include advanced age, multiple prescribers, frequent hospitalizations, cognitive impairment, and limited health literacy. Specific medication classes, such as anticholinergics, benzodiazepines, and antipsychotics, are frequently implicated in adverse outcomes and are prime candidates for deprescribing. Additionally, transitions of care, lack of medication reconciliation, and insufficient patient-provider communication further increase the risk of medication-related problems in multimorbid populations. Identifying these risk factors is essential for targeted deprescribing efforts.

Clinical Features

Clinical manifestations of polypharmacy-related harm are diverse and often nonspecific, including falls, delirium, orthostatic hypotension, gastrointestinal bleeding, renal dysfunction, and cognitive decline. In multimorbid patients, these symptoms may be mistakenly attributed to underlying disease rather than medication effects, leading to diagnostic overshadowing. A high index of suspicion, thorough medication reviews, and awareness of atypical presentations are necessary for clinicians to recognize and address medication-related harm effectively.

Diagnosis

The diagnosis of polypharmacy and identification of PIMs require systematic medication reconciliation, comprehensive review of medical history, and the use of validated tools such as the Beers Criteria, STOPP/START criteria, and the Medication Appropriateness Index. Incorporating patient-reported outcomes, such as quality of life and functional status, is increasingly recognized as essential in assessing the overall impact of polypharmacy and guiding deprescribing decisions. A multidisciplinary approach involving pharmacists, primary care providers, and specialists enhances diagnostic accuracy and intervention success.

Treatment & Management

Deprescribing should be a deliberate, patient-centered process. Key steps include: identifying medications without current indications, those with significant risk of harm, or those no longer aligned with the patient\"s goals of care. Shared decision-making is central, with explicit discussion of potential risks and benefits. Gradual tapering, close monitoring for withdrawal or disease recurrence, and regular follow-up are recommended. Non-pharmacological alternatives and lifestyle interventions should be considered whenever feasible. Documentation and communication with all care providers are crucial to ensure continuity and safety throughout the deprescribing process.

Recent Advances / Emerging Therapies

Recent advances include the integration of electronic health record (EHR)-based clinical decision support systems to flag PIMs and suggest deprescribing opportunities. Mobile health applications and digital health platforms facilitate patient engagement and medication tracking. There is growing evidence supporting pharmacist-led deprescribing interventions, which have demonstrated reductions in inappropriate medication use, ADRs, and hospitalizations. Emerging research is exploring the role of pharmacogenomics in personalizing deprescribing strategies, though routine clinical implementation remains limited.

Guideline Recommendations

Multiple professional organizations, including the American Geriatrics Society (AGS), the National Institute for Health and Care Excellence (NICE), and the Canadian Deprescribing Network, have issued evidence-based deprescribing guidelines. Core recommendations include regular medication review at each clinical encounter, prioritizing deprescribing for high-risk medications, and employing validated tools to assess medication appropriateness. Guidelines emphasize the importance of individualized care, shared decision-making, and the role of the interdisciplinary team. For multimorbid patients, guidelines recommend aligning deprescribing decisions with overall prognosis, patient preferences, and end-of-life care considerations.

Conclusion

Deprescribing in multimorbidity is an essential, evidence-based strategy to reduce polypharmacy-related harm and improve patient outcomes. Successful implementation requires a thorough understanding of the epidemiological trends, underlying pathophysiology, and clinical challenges associated with polypharmacy. Recent advances and guideline recommendations support a structured, patient-centered, and multidisciplinary approach tailored to the needs of complex patients. Ongoing research and innovation are likely to refine these strategies further, ensuring safer and more effective medication management for individuals with multiple chronic conditions.